Metraipolis › archive › dc_d3668b2ad565

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma — Europe PMC PMID:41720053

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41720053
DOI
10.1016/j.clinsp.2026.100869
License (as archived)
solo-consultazione
Archived
2026-11-05T15:27:57.221Z
SHA-256 of the archived text
bf2092cb58b071c0fc1497da1acdf6d4e833aab37fda30c86e79c89394c38a07
Stable URL of this page
https://metraipolis.com/documento/dc_d3668b2ad565

How to cite

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma — Europe PMC PMID:41720053 — Europe PMC (en), https://europepmc.org/article/MED/41720053 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d3668b2ad565 (Metraipolis archive dc_d3668b2ad565, sha256 bf2092cb58b071c0fc1497da1acdf6d4e833aab37fda30c86e79c89394c38a07)
BibTeX
@misc{dcd3668b2ad565,
  title = {Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma — Europe PMC PMID:41720053},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41720053},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d3668b2ad565; sha256 bf2092cb58b071c0fc1497da1acdf6d4e833aab37fda30c86e79c89394c38a07},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41720053. Agents can read the archived copy with the MCP tool read_document.